NCT01685021 2018-02-22
Study of Fc-Optimized Anti-CD19 Antibody (MOR00208) to Treat B-cell Acute Lymphoblastic Leukemia(B-ALL)
MorphoSys AG
Phase 2 Terminated
Clinical Trials
1 trialsPrecursor Cell Lymphoblastic Leukemia-Lymphoma × tafasitamab × Other hematologic neoplasm × Clear all